Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma
The American Journal of Pathology · 2024
DOI: 10.1016/j.ajpath.2024.02.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Pathology, 2024. Verfasst von Abraham L Bayer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Tufts University, Boston, Massachusetts. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Myeloid Differentiation Factor 88. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute Division of Intramural Research, National Institutes of Health.
Abstract (Originalsprache)
Cytotoxic CD8+ T cells are central to the antitumor immune response by releasing cytotoxic granules that kill tumor cells. They are activated by antigen-presenting cells, which become activated by DAMPs (damage associated molecular patterns) through MyD88. However, the suppressive tumor microenvironment promotes T-cell tolerance to tumor antigens, in part by enhancing the activity of immune checkpoint molecules that prevent CD8+ T-cell activation and cytotoxicity. MyD88 limits CD4+ T-cell activation during cardiac adaptation to stress. A similar mechanism is hypothesized to exist in CD8+ T cells that could be modulated to improve antitumor immunity. Herein, adoptive transfer of MyD88-/- CD8+ T cells in melanoma-bearing T-cell-deficient mice resulted in slower tumor growth, greater intratumoral T-cell accumulation, and higher melanoma cell death compared with transfer of wild-type CD8+ T cells. These findings were also observed in T-cell-specific MyD88-/- mice compared with wild-type littermates implanted with melanoma. Mechanistically, deletion of MyD88 enhanced CD8+ T-cell activation and survival, and T-cell receptor induced degranulation of cytotoxic molecules, overall improving the killing of melanoma cells. This enhanced cytotoxicity was retained in mice bearing tumors expressing the specific antigen for which cytotoxic T-cells were restricted. This study's results demonstrate a conserved mechanism for MyD88 in modulating CD8+ T-cell activation and represent a novel target in improving cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Tufts University, Boston, Massachusetts.
- Department of Genetics, Molecular and Cell Biology, Tufts University, Boston, Massachusetts.
- Department of Immunology, Tufts University, Boston, Massachusetts. Electronic address: pilar.alcaide@tufts.edu.
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute Division of Intramural Research
- National Institutes of Health
- American Heart Association
Zitieren
APA
Bayer, A. L., Padilla-Rolon, D., Smolgovsky, S., Hinds, P. W., & Alcaide, P. (2024). Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2024.02.012
Vancouver
Bayer AL, Padilla-Rolon D, Smolgovsky S, Hinds PW, Alcaide P. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma. The American Journal of Pathology. 2024. doi:10.1016/j.ajpath.2024.02.012
BibTeX
@article{Bayer2024,
author = {Bayer, Abraham L and Padilla-Rolon, Darwing and Smolgovsky, Sasha and Hinds, Philip W and Alcaide, Pilar},
title = {Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma},
journal = {The American Journal of Pathology},
year = {2024},
doi = {10.1016/j.ajpath.2024.02.012}
}
EUVIMED